Factors determining the remission of microprolactinomas after dopamine agonist withdrawal

Clinical Endocrinology

Volumn 72, Issue 4, 2010, Pages 507-511

  Huda, M S B ^a   Athauda, N B ^a   Teh, M M ^a   Carroll, P V ^a   Powrie, J K ^a  

^a GUY S HOSPITAL   (United Kingdom)

Author keywords

[No Author keywords available]

Indexed keywords

BROMOCRIPTINE; CABERGOLINE; DOPAMINE RECEPTOR STIMULATING AGENT; PERGOLIDE;

ADULT; ARTICLE; CLINICAL ARTICLE; COHORT ANALYSIS; DRUG WITHDRAWAL; FEMALE; HUMAN; HYPOPHYSIS; MALE; NUCLEAR MAGNETIC RESONANCE IMAGING; PRIORITY JOURNAL; PROLACTINOMA; PROSPECTIVE STUDY; RELAPSE; REMISSION; TREATMENT DURATION;

ADULT; COHORT STUDIES; DOPAMINE AGONISTS; FEMALE; HUMANS; MAGNETIC RESONANCE IMAGING; MALE; MIDDLE AGED; PROLACTIN; PROLACTINOMA; PROSPECTIVE STUDIES; RECURRENCE; WITHHOLDING TREATMENT;

EID: 77749301563     PISSN: 03000664     EISSN: 13652265     Source Type: Journal    
DOI: 10.1111/j.1365-2265.2009.03657.x     Document Type: Article

References (23)

1. Bevan, J.S., Webster, J., Burke, C.W. et al. (1992) Dopamine agonists and pituitary tumor shrinkage. Endocrine Reviews, 13, 220 240.
2. Molitch, M.E., Elton, R.L., Blackwell, R.E. et al. (1985) Bromocriptine as primary therapy for prolactin-secreting macroadenomas: results of a prospective multicenter study. Journal of Clinical Endocrinology and Metabolism, 60, 698 705.
3. Vance, M.L., Evans, W.S. Thorner, M.O. (1984) Drugs five years later. Bromocriptine. Annals of Internal Medicine, 100, 78 91.
4. Schade, R., Andersohn, F., Suissa, S. et al. (2007) Dopamine agonists and the risk of cardiac-valve regurgitation. New England Journal of Medicine, 356, 29 38.
5. Casanueva, F.F., Molitch, M.E., Schlechte, J.A. et al. (2006) Guidelines of the Pituitary Society for the diagnosis and management of prolactinomas. Clinical Endocrinology, 65, 265 273.
6. Clayton, R.N. Wass, J.A. (1997) Pituitary tumours: recommendations for service provision and guidelines for management of patients. Summary of a consensus statement of a working party from the Endocrinology and Diabetes Committee of The Royal College of Physicians and the Society for Endocrinology in conjunction with the Research Unit of the Royal College of Physicians. Journal of the Royal College of Physicians of London, 31, 628 636.
7. Biswas, M., Smith, J., Jadon, D. et al. (2005) Long-term remission following withdrawal of dopamine agonist therapy in subjects with microprolactinomas. Clinical Endocrinology, 63, 26 31.
8. Cannavo, S., Curto, L., Squadrito, S. et al. (1999) Cabergoline: a first-choice treatment in patients with previously untreated prolactin-secreting pituitary adenoma. Journal of Endocrinological Investigation, 22, 354 359.
9. Colao, A., Di, S.A., Cappabianca, P. et al. (2003) Withdrawal of long-term cabergoline therapy for tumoral and nontumoral hyperprolactinemia. New England Journal of Medicine, 349, 2023 2033.
10. Di Sarno, A., Landi, M.L., Marzullo, P. et al. (2000) The effect of quinagolide and cabergoline, two selective dopamine receptor type 2 agonists, in the treatment of prolactinomas. Clinical Endocrinology, 53, 53 60.
11. Ferrari, C., Paracchi, A., Mattei, A.M. et al. (1992) Cabergoline in the long-term therapy of hyperprolactinemic disorders. Acta Endocrinology, 126, 489 494.
12. Johnston, D.G., Hall, K., Kendall-Taylor, P. et al. (1984) Effect of dopamine agonist withdrawal after long-term therapy in prolactinomas. Studies with high-definition computerised tomography. Lancet, 2, 187 192.
13. Moriondo, P., Travaglini, P., Nissim, M. et al. (1985) Bromocriptine treatment of microprolactinomas: evidence of stable prolactin decrease after drug withdrawal. Journal of Clinical Endocrinology and Metabolism, 60, 764 772.
14. Muratori, M., Arosio, M., Gambino, G. et al. (1997) Use of cabergoline in the long-term treatment of hyperprolactinemic and acromegalic patients. Journal of Endocrinological Investigation, 20, 537 546.
15. Passos, V.Q., Souza, J.J., Musolino, N.R. et al. (2002) Long-term follow-up of prolactinomas: normoprolactinemia after bromocriptine withdrawal. Journal of Clinical Endocrinology and Metabolism, 87, 3578 3582.
16. Rasmussen, C., Bergh, T. Wide, L. (1987) Prolactin secretion and menstrual function after long-term bromocriptine treatment. Fertility and Sterility, 48, 550 554.
17. van't Verlaat, J.W. Croughs, R.J. (1991) Withdrawal of bromocriptine after long-term therapy for macroprolactinomas; effect on plasma prolactin and tumour size. Clinical Endocrinology, 34, 175 178.
18. Wang, C., Lam, K.S., Ma, J.T. et al. (1987) Long-term treatment of hyperprolactinaemia with bromocriptine: effect of drug withdrawal. Clinical Endocrinology, 27, 363 371.
19. Zarate, A., Canales, E.S., Cano, C. et al. (1983) Follow-up of patients with prolactinomas after discontinuation of long-term therapy with bromocriptine. Acta Endocrinology, 104, 139 142.
20. Mehmet, S. Powrie, J.K. (2003) A survey of dopamine agonist withdrawal policy in UK endocrinologists treating patients with prolactinomas. Clinical Endocrinology, 58, 111 113.
21. Colao, A., Di, S.A., Guerra, E. et al. (2007) Predictors of remission of hyperprolactinaemia after long-term withdrawal of cabergoline therapy. Clinical Endocrinology, 67, 426 433.
22. Sisam, D.A., Sheehan, J.P. Sheeler, L.R. (1987) The natural history of untreated microprolactinomas. Fertility and Sterility, 48, 67 71.
23. Schlechte, J., Dolan, K., Sherman, B. et al. (1989) The natural history of untreated hyperprolactinemia: a prospective analysis. Journal of Clinical Endocrinology and Metabolism, 68, 412 418.